PROPRIETARY ONCOLOGY PIPELINE OF HUMAN MONOCLONAL ANTIBODIES

Viventia has taken three product candidates to the clinic and has several more in preclinical development. The Company's product candidates represent promising and differentiated new cancer therapies that combine the selectivity of tumor targeting antibodies with the potency of traditional cancer therapies:

• Vicinium™ - Phase III clinical trial plans reviewed by the FDA/EMEA for non-muscle invasive bladder cancer
  
  
• Proxinium™ - Orphan Drug designation for the treatment of EpCAM positive SCCHN in the United States and the European Union
  
  
• VB6-845 - Formulated for systemic administration for the treatment of metastasizing solid tumors
  
  More information on our Product Pipeline page
  

PROPRIETARY NON-IMMUNOGENIC CYTOTOXIC PAYLOAD – DE-BOUGANIN

Viventia has developed a protein payload that when coupled to an antibody increases its therapeutic potential. This approach addresses the limitations of native antibodies as monotherapies, which are often not sufficiently potent to provide prolonged clinical benefit. Viventia's approach represents a significant evolution in the field of antibody technology that addresses key current limitations associated with both naked and conjugated antibody approaches. The principal advantages of Viventia's platform are:

• Small antibody fragments facilitate effective tumor penetration
  
  
• Payloads are attached to antibody fragments through recombinant engineering, creating stable fusion proteins, limiting non-specific toxicity
  
  
• Tumor-activated payloads are exceptionally potent and are designed to specifically activate within the cell and to remain inert outside the cell
  
  
• Proprietary de-immunized payload allows for repeat systemic administration
  
  
• Immunotoxins kill target cells directly rather than by relying on the patient’s immune system
  
  More details on our Cytotoxic Payload page
  

PROPRIETARY IMMUNE-DRIVEN ANTIBODY PLATFORM (IDAP)

Viventia offers a comprehensive, integrated R&D engine, IDAP, capable of isolating human antibodies that can be used to identify new targets and/or in the development of antibody-based products against those targets.

• Proprietary target discovery platform successfully applied to identify over 14 oncology drug targets including several novel and proprietary protein variants
  

• Human immune response used to generate highly specific antibody libraries using proprietary technologies
  
  More information on our Discovery Platform page

cGMP FACILITY PROVIDES ADVANTAGES OF IN-HOUSE CLINICAL STAGE PRODUCTION WITH MANUFACTURING PROCESSES TRANSFERABLE TO COMMERCIAL SCALE PRODUCTION

Viventia’s production facility permits control over product development from bench to bedside and the realization of quality drug product for the purpose of meeting pre-clinical and clinical needs.

• Production infrastructure, including process development and quality systems
  
  
• Streamlined and flexible approach to production flowing rapidly from R&D to manufacturing
  
  
• Scalable production processes and capabilities facilitates advancement from preclinical through to late stage (Phase III) clinical development

• Processes are easily transferable to commercial scale production
  
  See our cGMP Manufacturing page